215 related articles for article (PubMed ID: 34020377)
1. Training of computational algorithms to predict NAFLD activity score and fibrosis stage from liver histopathology slides.
Qu H; Minacapelli CD; Tait C; Gupta K; Bhurwal A; Catalano C; Dafalla R; Metaxas D; Rustgi VK
Comput Methods Programs Biomed; 2021 Aug; 207():106153. PubMed ID: 34020377
[TBL] [Abstract][Full Text] [Related]
2. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
4. Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.
Heinemann F; Gross P; Zeveleva S; Qian HS; Hill J; Höfer A; Jonigk D; Diehl AM; Abdelmalek M; Lenter MC; Pullen SS; Guarnieri P; Stierstorfer B
Sci Rep; 2022 Nov; 12(1):19236. PubMed ID: 36357500
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease.
Monteiro JM; Monteiro GM; Caroli-Bottino A; Pannain VL
Anal Cell Pathol (Amst); 2014; 2014():526979. PubMed ID: 25763333
[TBL] [Abstract][Full Text] [Related]
6. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Lee J; Westphal M; Vali Y; Boursier J; Petta S; Ostroff R; Alexander L; Chen Y; Fournier C; Geier A; Francque S; Wonders K; Tiniakos D; Bedossa P; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison S; Cobbold J; Holleboom AG; Yki-Järvinen H; Crespo J; Ekstedt M; Aithal GP; Bugianesi E; Romero-Gomez M; Torstenson R; Karsdal M; Yunis C; Schattenberg JM; Schuppan D; Ratziu V; Brass C; Duffin K; Zwinderman K; Pavlides M; Anstee QM; Bossuyt PM;
Hepatology; 2023 Jul; 78(1):258-271. PubMed ID: 36994719
[TBL] [Abstract][Full Text] [Related]
7. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
10. Application of Scores Assessing Histological Activity and Estimated Long-Term Risk Analysis of Hepatic Decompensation of Non-Alcoholic Fatty Liver Disease in Individuals Undergoing Bariatric Surgery.
Hatto M; Ivano VK; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2023 May; 33(5):1580-1586. PubMed ID: 37004688
[TBL] [Abstract][Full Text] [Related]
11. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
[TBL] [Abstract][Full Text] [Related]
12. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
13. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
[TBL] [Abstract][Full Text] [Related]
14. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
Jamali R; Razavizade M; Arj A; Aarabi MH
World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
[TBL] [Abstract][Full Text] [Related]
15. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
[TBL] [Abstract][Full Text] [Related]
16. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.
Feng G; Zheng KI; Li YY; Rios RS; Zhu PW; Pan XY; Li G; Ma HL; Tang LJ; Byrne CD; Targher G; He N; Mi M; Chen YP; Zheng MH
J Hepatobiliary Pancreat Sci; 2021 Jul; 28(7):593-603. PubMed ID: 33908180
[TBL] [Abstract][Full Text] [Related]
17. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
Santiago-Rolón A; Purcell D; Rosado K; Toro DH
P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
[TBL] [Abstract][Full Text] [Related]
19. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
[TBL] [Abstract][Full Text] [Related]
20. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
